SI2580243T1 - Protitelesa proti humanemu CD38 - Google Patents

Protitelesa proti humanemu CD38

Info

Publication number
SI2580243T1
SI2580243T1 SI201131831T SI201131831T SI2580243T1 SI 2580243 T1 SI2580243 T1 SI 2580243T1 SI 201131831 T SI201131831 T SI 201131831T SI 201131831 T SI201131831 T SI 201131831T SI 2580243 T1 SI2580243 T1 SI 2580243T1
Authority
SI
Slovenia
Prior art keywords
antibodies against
against human
human
antibodies
Prior art date
Application number
SI201131831T
Other languages
English (en)
Inventor
Michel De Weers
Tim Walseth
Jan Van De Winkel
Tom Vink
Paul Parren
Original Assignee
Genmab A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab A/S filed Critical Genmab A/S
Publication of SI2580243T1 publication Critical patent/SI2580243T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91148—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
SI201131831T 2010-06-09 2011-06-08 Protitelesa proti humanemu CD38 SI2580243T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35308210P 2010-06-09 2010-06-09
DKPA201000498 2010-06-09
EP11726381.4A EP2580243B1 (en) 2010-06-09 2011-06-08 Antibodies against human cd38
PCT/EP2011/059507 WO2011154453A1 (en) 2010-06-09 2011-06-08 Antibodies against human cd38

Publications (1)

Publication Number Publication Date
SI2580243T1 true SI2580243T1 (sl) 2020-02-28

Family

ID=44454551

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201131831T SI2580243T1 (sl) 2010-06-09 2011-06-08 Protitelesa proti humanemu CD38

Country Status (11)

Country Link
US (4) US9249226B2 (sl)
EP (2) EP2580243B1 (sl)
JP (5) JP6093696B2 (sl)
CY (1) CY1122490T1 (sl)
DK (1) DK2580243T3 (sl)
LT (1) LT2580243T (sl)
PL (1) PL2580243T3 (sl)
PT (1) PT2580243T (sl)
RS (1) RS59769B1 (sl)
SI (1) SI2580243T1 (sl)
WO (1) WO2011154453A1 (sl)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
DK2580243T3 (da) * 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
CN105585630B (zh) 2010-07-29 2020-09-15 Xencor公司 具有修改的等电点的抗体
BR112014009925B1 (pt) 2011-10-28 2022-09-20 Teva Pharmaceuticals Australia Pty Ltd Construtores de polipeptídeos e seus usos
AU2013322806C1 (en) * 2012-09-25 2018-03-08 Morphosys Ag Combinations and uses thereof
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
KR102211837B1 (ko) 2013-01-14 2021-02-03 젠코어 인코포레이티드 신규한 이형이량체 단백질
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
AU2014232416B2 (en) 2013-03-15 2017-09-28 Xencor, Inc. Modulation of T Cells with Bispecific Antibodies and FC Fusions
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
EA033115B1 (ru) 2013-04-29 2019-08-30 Тева Фармасьютикалз Острэйлиа Пти Лтд. АНТИТЕЛА ПРОТИВ CD38 И СЛИТЫЕ БЕЛКИ С ОСЛАБЛЕННЫМ ИНТЕРФЕРОНОМ АЛЬФА-2b
EP3021866A4 (en) * 2013-07-15 2017-02-22 The Board of Trustees of the Leland Stanford Junior University Medical uses of cd38 agonists
CN103513040B (zh) * 2013-10-16 2015-03-11 常晓天 蛋白cd38在制备类风湿性关节炎诊断标记物中的应用
AP2016009222A0 (en) 2013-11-04 2016-05-31 Glenmark Pharmaceuticals Sa Production of t cell retargeting hetero-dimeric immunoglobulins
JP2017506640A (ja) * 2014-02-14 2017-03-09 セントローズ， エルエルシー 細胞外標的化薬物共役体
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
RS59907B1 (sr) * 2014-03-28 2020-03-31 Xencor Inc Bispecifična antitela koja se vezuju za cd38 i cd3
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
KR102586588B1 (ko) 2014-09-09 2023-10-06 얀센 바이오테크 인코포레이티드 항-cd38 항체를 사용하는 병용 요법
KR102639037B1 (ko) 2014-10-29 2024-02-20 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 인터페론 α2b 변이체
US11773166B2 (en) * 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
AU2015353416C1 (en) 2014-11-26 2022-01-27 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
IL252480B2 (en) 2014-11-26 2023-12-01 Xencor Inc Heterodimeric antibodies that bind CD3 and tumor antigens
SG11201704390PA (en) 2014-12-04 2017-06-29 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemia
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
MA41375A (fr) * 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
CN113527495A (zh) 2015-04-08 2021-10-22 索伦托药业有限公司 与cd38结合的抗体治疗剂
WO2016180958A1 (en) 2015-05-13 2016-11-17 Morphosys Ag Treatment for multiple myeloma (mm)
UA124143C2 (uk) * 2015-05-20 2021-07-28 Янссен Байотек, Інк. Антитіла до cd38 для лікування амілоїдозу, викликаного відкладеннями легких ланцюгів імуноглобулінів, і інших cd38-позитивних злоякісних гематологічних новоутворень
WO2016189532A1 (en) * 2015-05-26 2016-12-01 Ramot At Tel-Aviv University Ltd. Targeted lipid particles for systemic delivery of nucleic acid molecules to leukocytes
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
MX2018000261A (es) * 2015-06-24 2018-03-08 Janssen Biotech Inc Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38.
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
BR112018008011A2 (pt) 2015-10-25 2018-10-30 Sanofi proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv
PT3370770T (pt) 2015-11-03 2021-02-22 Janssen Biotech Inc Formulações subcutâneas de anticorpos anti-cd38 e suas utilizações
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
IL260750B2 (en) 2016-03-04 2024-02-01 Morphosys Ag Clinical evaluation of protein-M response in multiple myeloma
RS64771B1 (sr) * 2016-04-13 2023-11-30 Sanofi Sa Trispecifični i/ili trovalentni vezujući proteini
CN109476732B (zh) 2016-04-13 2024-03-22 赛诺菲 三特异性和/或三价结合蛋白
RU2767357C2 (ru) 2016-06-14 2022-03-17 Ксенкор, Инк. Биспецифические антитела-ингибиторы контрольных точек
EP3474895A1 (en) * 2016-06-28 2019-05-01 UMC Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
MX2018016265A (es) 2016-06-28 2019-07-04 Xencor Inc Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
EP3487506A1 (en) 2016-07-20 2019-05-29 Hybrigenics SA Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3526240A1 (en) 2016-10-14 2019-08-21 Xencor, Inc. Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments
MX2019004621A (es) 2016-11-02 2019-11-28 Engmab Sarl Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple.
CA3043356A1 (en) 2016-11-09 2018-05-17 Musc Foundation For Research Development Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
WO2018098348A1 (en) * 2016-11-23 2018-05-31 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a cd38 inhibitor and methods of use thereof
CA3045386A1 (en) * 2016-12-09 2018-06-14 Onkimmune Limited Engineered natural killer cells and uses thereof
JP7359700B2 (ja) * 2017-06-20 2023-10-11 ソレント・セラピューティクス・インコーポレイテッド Ｃｄ３８抗体薬物コンジュゲート
CN111132733A (zh) 2017-06-30 2020-05-08 Xencor股份有限公司 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
EP3434692A1 (en) * 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
BR112020003670A2 (pt) 2017-08-22 2020-09-01 Sanabio, Llc receptores de interferon solúveis e usos dos mesmos
CN111133007A (zh) 2017-09-13 2020-05-08 特尼奥生物股份有限公司 与胞外酶结合的重链抗体
EP3694882A2 (en) 2017-10-10 2020-08-19 Sanofi Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
AU2018359527A1 (en) 2017-10-31 2020-05-07 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
CN111542545A (zh) 2017-11-03 2020-08-14 索伦托治疗有限公司 Cd38定向嵌合抗原受体构建体
EP3706793A1 (en) 2017-11-08 2020-09-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CN108318689A (zh) * 2018-04-09 2018-07-24 北京大学深圳研究生院 一种多发性骨髓瘤的诊断方法
MX2020010910A (es) 2018-04-18 2021-02-09 Xencor Inc Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
BR112020026432A2 (pt) * 2018-07-13 2021-03-23 Genmab A/S variante de anticorpo, ácido nucleico isolado, vetor de expressão, ácido nucleico, combinação de ácidos nucleicos, veículo de dispensação, célula hospedeira recombinante, métodos para produção de uma variante de um anticorpo, para aumentar pelo menos uma função efetora de um anticorpo parental e para tratar uma doença, anticorpo, composição, composição farmacêutica, e, variante de anticorpo para uso
MA53123A (fr) 2018-07-13 2021-05-19 Genmab As Thérapie à médiation par trogocytose utilisant des anticorps cd38
EP3861016A2 (en) 2018-10-03 2021-08-11 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
EP3864043A1 (en) 2018-10-09 2021-08-18 Sanofi Trispecific anti-cd38, anti-cd28, and anti-cd3 binding proteins and methods of use for treating viral infection
EP3870611A1 (en) 2018-10-26 2021-09-01 TeneoBio, Inc. Heavy chain antibodies binding to cd38
JP2022512294A (ja) 2018-12-14 2022-02-03 モルフォシス・アーゲー 抗体製剤
JP2022520572A (ja) 2019-02-12 2022-03-31 プロシーナ バイオサイエンシーズ リミテッド 免疫グロブリン軽鎖に対するモノクローナル抗体と、抗体産生細胞および他の免疫細胞上のｃｄ３８細胞膜分子に対するモノクローナル抗体の組み合わせによるａｌアミロイドーシスの処置
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
JP2022522889A (ja) 2019-03-05 2022-04-20 プロシーナ バイオサイエンシーズ リミテッド Ａｌアミロイドーシスを処置する方法
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
JP2022537134A (ja) 2019-06-10 2022-08-24 武田薬品工業株式会社 Ｃｄ３８抗体を使用する併用療法
WO2020261219A1 (en) 2019-06-27 2020-12-30 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
CA3158579A1 (en) 2019-12-18 2021-06-24 Pranjali DALVI Heavy chain antibodies binding to cd38
WO2021144457A1 (en) 2020-01-16 2021-07-22 Genmab A/S Formulations of cd38 antibodies and uses thereof
IL295896A (en) 2020-02-26 2022-10-01 Biograph 55 Inc c19 c38 bispecific antibodies
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US20220023344A1 (en) 2020-06-26 2022-01-27 Crispr Therapeutics Ag Allogeneic cell therapy of acute lymphoblastic leukemia using genetically engineered t cells targeting cd19
WO2022040482A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
US20230398219A1 (en) 2020-09-14 2023-12-14 Vor Biopharma Inc. Compositions and methods for cd38 modification
WO2022137186A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
AR125852A1 (es) 2021-05-12 2023-08-16 Crispr Therapeutics Ag Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en tratamiento de tumores sólidos
WO2022238962A1 (en) 2021-05-12 2022-11-17 Crispr Therapeutics Ag Genetically engineered immune cells targeting cd70 for use in treating hematopoietic malignancies
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
CA3225405A1 (en) 2021-07-28 2023-02-02 Alexander Joachim Paul Ungewickell Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers
CN114409788B (zh) * 2022-03-04 2022-10-04 四川大学华西医院 抗cd38的抗体及其应用
WO2023192321A2 (en) * 2022-03-28 2023-10-05 Vygen-Bio, Inc. Genetically engineered antibody resistant (gear) cells for adoptive cellular therapy

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4681581A (en) 1983-12-05 1987-07-21 Coates Fredrica V Adjustable size diaper and folding method therefor
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
HUT53672A (en) 1988-02-25 1990-11-28 Gen Hospital Corp Quick immunoselective cloning process
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5879936A (en) 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JP3070763B2 (ja) 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
ATE264916T1 (de) 1989-12-22 2004-05-15 Applied Research Systems Dns-konstrukten zur aktivierung und veränderung der expression von endogenen genen
US5891693A (en) 1990-01-25 1999-04-06 Alusuisse Holdings A.G. Recombinant DNA methods vectors and host cells
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
AU658370B2 (en) 1990-07-13 1995-04-13 General Hospital Corporation, The CD53 cell surface antigen and use thereof
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
WO1992022645A1 (en) 1991-06-14 1992-12-23 Genpharm International, Inc. Transgenic immunodeficient non-human animals
EP0593592B1 (en) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
AU6123894A (en) 1993-01-29 1994-08-15 Board Of Trustees Of The Leland Stanford Junior University Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
DK0804070T3 (da) 1993-03-09 2000-08-07 Genzyme Corp Fremgangsmåde til isolering af proteiner fra mælk
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
AU693097B2 (en) 1993-06-04 1998-06-25 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for treating kaposi's sarcoma with antisense oligonucleotides
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5879687A (en) 1994-04-22 1999-03-09 Corixa Corporation Methods for enhancement of protective immune responses
WO1996005298A1 (en) 1994-08-09 1996-02-22 Ciba-Geigy Ag Antitumor antisense oligonucleotides
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
WO1997014709A1 (en) 1995-10-13 1997-04-24 F. Hoffmann-La Roche Ag Antisense oligomers
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
AU708096B2 (en) 1995-11-21 1999-07-29 Icn Pharmaceuticals, Inc. Inhibition of tumor growth by antisense oligonucleotides for IL-8 and IL-8 receptor
CA2246503A1 (en) 1996-02-15 1997-08-21 National Institutes Of Health Rnase l activators and antisense oligonucleotides effective to treat rsv infections
ES2112211B1 (es) 1996-03-26 1998-12-16 Univ Salamanca Procedimiento para el estudio del ciclo celular de subpoblaciones de celulas presentes en muestras celulares heterogeneas.
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
WO1998016245A1 (fr) 1996-10-15 1998-04-23 Shionogi & Co., Ltd. Procede de determination d'un auto-anticorps
WO1998016254A1 (en) 1996-10-17 1998-04-23 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
WO2000006194A2 (en) 1997-02-05 2000-02-10 Biotransplant, Inc. Depletion of cells responsible for antibody-mediated graft rejection
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
WO1998050435A1 (en) 1997-05-02 1998-11-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunotoxins, comprising an onc protein, directed against malignant cells
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
CA2248762A1 (en) 1997-10-22 1999-04-22 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of tnf-.alpha.
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
ATE414536T1 (de) 1998-08-11 2008-12-15 Biogen Idec Inc Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20- antikörpern
AU766403C (en) 1998-09-04 2004-05-27 Aventis Pasteur Limited Treatment of cervical cancer
US6387888B1 (en) 1998-09-30 2002-05-14 American Foundation For Biological Research, Inc. Immunotherapy of cancer through expression of truncated tumor or tumor-associated antigen
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US20050037969A1 (en) 1999-05-14 2005-02-17 Arbor Vita Corporation Molecular interactions in hematopoietic cells
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
EP1210372B1 (en) 1999-07-29 2008-01-23 Medarex, Inc. Human monoclonal antibodies to her2/neu
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
CA2424643A1 (en) 2000-10-17 2002-04-25 Trudeau Institute, Inc. Cd38 modulated chemotaxis
US20070042436A1 (en) 2000-10-17 2007-02-22 Lund Frances E CD38 modulated chemotaxis
US6713055B2 (en) 2000-11-27 2004-03-30 Geron Corporation Glycosyltransferase vectors for treating cancer
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
JP4298498B2 (ja) 2001-06-13 2009-07-22 ゲンマブ エー／エス 上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
CA2456648C (en) 2001-08-23 2011-08-16 Genmab A/S Human antibodies specific for interleukin 15 (il-15)
US7247304B2 (en) 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
US20040166490A1 (en) 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
CN1305905C (zh) 2002-03-22 2007-03-21 Aprogen株式会社 人源化抗体及其制备方法
US20040019915A1 (en) 2002-04-01 2004-01-29 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
JP4741838B2 (ja) 2002-07-31 2011-08-10 シアトル ジェネティクス，インコーポレーテッド 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用
EP1393720A1 (en) 2002-08-27 2004-03-03 Universiteit Utrecht Vesicle-encapsulated corticosteroids for treatment of cancer
KR101348472B1 (ko) 2002-10-17 2014-01-07 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
KR20050086628A (ko) 2002-11-15 2005-08-30 젠맵 에이/에스 Ｃｄ25에 대한 인간 모노클로날 항체
JP4739763B2 (ja) 2002-12-16 2011-08-03 ゲンマブ エー／エス インターロイキン８（ｉｌ−８）に対するヒトモノクローナル抗体
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
CA2542840A1 (en) 2003-10-22 2005-05-12 University Of Rochester Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis
ATE474599T1 (de) 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonisten-anti-cd40- monoklonalen antikörpern zur behandlung von multiplem myelom
PT2489364E (pt) 2003-11-06 2015-04-16 Seattle Genetics Inc Compostos de monometilvalina conjugados com anticorpos
BRPI0507489A (pt) 2004-02-06 2007-07-10 Morphosys Ag anticorpos humanos de anti-cd38 e para os seus usos
US8263746B2 (en) 2004-02-06 2012-09-11 Morphosys Ag Anti-CD38 human antibodies and uses thereof
US20050266008A1 (en) 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies
US20060019303A1 (en) 2004-07-23 2006-01-26 Boehringer Ingelheim Pharmaceuticals, Inc. Method to identify and analyze genes having modified expression in stimulated T cells
CA2580981C (en) 2004-09-22 2013-10-22 Kirin Beer Kabushiki Kaisha Stabilized human igg4 antibodies
EP2567976B1 (en) 2005-03-23 2017-07-19 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP2799451A1 (en) * 2005-05-24 2014-11-05 MorphoSys AG Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38
WO2007059782A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
JP5476122B2 (ja) 2006-09-26 2014-04-23 ゲンマブ エー／エス Ｃｄ３８発現腫瘍の併用処置法
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
WO2009083009A2 (en) 2008-01-03 2009-07-09 Genmab A/S Monoclonal antibodies against cd32b
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
KR102586588B1 (ko) 2014-09-09 2023-10-06 얀센 바이오테크 인코포레이티드 항-cd38 항체를 사용하는 병용 요법
SG11201704390PA (en) 2014-12-04 2017-06-29 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemia
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
MX2018000261A (es) 2015-06-24 2018-03-08 Janssen Biotech Inc Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38.

Also Published As

Publication number Publication date
JP2020031654A (ja) 2020-03-05
EP3613774A1 (en) 2020-02-26
US9249226B2 (en) 2016-02-02
DK2580243T3 (da) 2020-01-13
WO2011154453A1 (en) 2011-12-15
JP2017140025A (ja) 2017-08-17
EP2580243A1 (en) 2013-04-17
PL2580243T3 (pl) 2020-05-18
JP6093696B2 (ja) 2017-03-08
CY1122490T1 (el) 2021-01-27
US20220204636A1 (en) 2022-06-30
JP2013539352A (ja) 2013-10-24
US20130209355A1 (en) 2013-08-15
RS59769B1 (sr) 2020-02-28
US9944711B2 (en) 2018-04-17
JP6609580B2 (ja) 2019-11-20
EP2580243B1 (en) 2019-10-16
US20180298106A1 (en) 2018-10-18
LT2580243T (lt) 2020-01-27
JP2022050388A (ja) 2022-03-30
PT2580243T (pt) 2020-01-22
JP2024028722A (ja) 2024-03-05
US11230604B2 (en) 2022-01-25
US20160237161A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
HRP20181320T1 (hr) Ljudska anti-tau protutijela
HRP20180952T1 (hr) Anti-dll3 antitijelo
RS59769B1 (sr) Antitela protiv humanog cd38
ZA201209004B (en) Anti-fgfr2 antibodies
GB201000467D0 (en) Antibodies
IL221288A0 (en) Therapeutic methods using anti-cd200 antibodies
PL2581113T3 (pl) Przeciwciało anty-tim-3
IL221371A0 (en) Anti-lrp6 antibodies
PL2616489T3 (pl) Przeciwciało anty-huTNFR1
HK1194388A1 (zh) 抗缺刻蛋白 抗體
PT2603528T (pt) Anticorpos glicosilados em fab
GB201020738D0 (en) Antibodies
GB201002238D0 (en) Antibodies
ZA201302459B (en) Antibodies
EP2650367A4 (en) HUMAN MONOCLONAL ANTIBODY
GB201007957D0 (en) Antibody
HUE048721T2 (hu) Humán CD38 elleni ellenanyagok
IL226635B (en) Human anti-sod1 antibodies
GB201020751D0 (en) Antibodies
GB201005062D0 (en) Antibodies
GB201017780D0 (en) Antibody